Amicus Therapeutics Announces Timing of Third Quarter 2014 Financial Results, Upcoming Scientific Conference and Other Corporate Updates

CRANBURY, N.J., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics FOLD today announced that a conference call and live audio webcast are scheduled for Thursday, November 6, 2014 at 5:00 p.m. ET to discuss financial results for the third quarter ended September 30, 2014.

The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer, who returned to Amicus from temporary active military duty today, Monday, November 3, 2014. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call at 5:00 p.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register and download and install any necessary software. A telephonic replay of the call will be available for seven days beginning at 8:00 p.m. ET on November 6, 2014. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 17044123.

Furthermore, Amicus announced that additional data from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl ("migalastat") in Fabry disease patients with amenable mutations will be presented in a poster at the American Society of Nephrology (ASN) Kidney Week 2014 in Philadelphia.

The schedule for the poster presentation is as follows:

About Amicus Therapeutics

Amicus Therapeutics FOLD is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS-1.

FOLD-G